Neoantigens in cancer immunotherapy

被引：3675

作者：

Schumacher, Ton N. ^{[1
]}

Schreiber, Robert D. ^{[2
]}

机构：

[1] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands

[2] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA

来源：

SCIENCE | 2015年 / 348卷 / 6230期

关键词：

EXOME ANALYSIS REVEALS; MHC CLASS-I; T-CELLS; PD-1; BLOCKADE; NEO-ANTIGENS; CD4+T CELLS; LYMPHOCYTES; THERAPY; IDENTIFICATION; NEOEPITOPES;

D O I：

10.1126/science.aaa4971

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The clinical relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. However, the nature of the antigens that allow the immune system to distinguish cancer cells from noncancer cells has long remained obscure. Recent technological innovations have made it possible to dissect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is a major factor in the activity of clinical immunotherapies. These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.

引用

页码：69 / 74

页数：6

共 52 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2] Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside [J].

Boisguerin, V. ;

Castle, J. C. ;

Loewer, M. ;

Diekmann, J. ;

Mueller, F. ;

Britten, C. M. ;

Kreiter, S. ;

Tuereci, Oe ;

Sahin, U. .

BRITISH JOURNAL OF CANCER, 2014, 111 (08) :1469-1475

[3] Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival [J].

Brown, Scott D. ;

Warren, Rene L. ;

Gibb, Ewan A. ;

Martin, Spencer D. ;

Spinelli, John J. ;

Nelson, Brad H. ;

Holt, Robert A. .

GENOME RESEARCH, 2014, 24 (05) :743-750

[4] Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways:: β2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors [J].

Cabrera, CM ;

Jiménez, P ;

Cabrera, T ;

Esparza, C ;

Ruiz-Cabello, F ;

Garrido, F .

TISSUE ANTIGENS, 2003, 61 (03) :211-219

[5] Properties of MHC Class I Presented Peptides That Enhance Immunogenicity [J].

Calis, Jorg J. A. ;

Maybeno, Matt ;

Greenbaum, Jason A. ;

Weiskopf, Daniela ;

De Silva, Aruna D. ;

Sette, Alessandro ;

Kesmir, Can ;

Peters, Bjoern .

PLOS COMPUTATIONAL BIOLOGY, 2013, 9 (10)

[6] Exploiting the Mutanome for Tumor Vaccination [J].

Castle, John C. ;

Kreiter, Sebastian ;

Diekmann, Jan ;

Loewer, Martin ;

Van de Roemer, Niels ;

de Graaf, Jos ;

Selmi, Abderraouf ;

Diken, Mustafa ;

Boegel, Sebastian ;

Paret, Claudia ;

Koslowski, Michael ;

Kuhn, Andreas N. ;

Britten, Cedrik M. ;

Huber, Christoph ;

Tuereci, Oezlem ;

Sahin, Ugur .

CANCER RESEARCH, 2012, 72 (05) :1081-1091

[7] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

[8] Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity [J].

Duan, Fei ;

Duitama, Jorge ;

Al Seesi, Sahar ;

Ayres, Cory M. ;

Corcelli, Steven A. ;

Pawashe, Arpita P. ;

Blanchard, Tatiana ;

McMahon, David ;

Sidney, John ;

Sette, Alessandro ;

Baker, Brian M. ;

Mandoiu, Ion I. ;

Srivastava, Pramod K. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (11) :2231-2248

[9] Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma [J].

Dudley, Mark E. ;

Gross, Colin A. ;

Somerville, Robert P. T. ;

Hong, Young ;

Schaub, Nicholas P. ;

Rosati, Shannon F. ;

White, Donald E. ;

Nathan, Debbie ;

Restifo, Nicholas P. ;

Steinberg, Seth M. ;

Wunderlich, John R. ;

Kammula, Udai S. ;

Sherry, Richard M. ;

Yang, James C. ;

Phan, Giao Q. ;

Hughes, Marybeth S. ;

Laurencot, Carolyn M. ;

Rosenberg, Steven A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) :2152-U144

[10] Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens [J].

Dudley, ME ;

Roopenian, DC .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :441-447

← 1 2 3 4 5 6 →